{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:00:13Z","timestamp":1793012413656,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.eururo.2017.06.021","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T09:20:49Z","timestamp":1499764849000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial"],"prefix":"10.1016","volume":"73","author":[{"given":"Christopher C.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Helle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie D.","family":"Foss\u00e5","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Chodacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Wiechno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Logue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihalj","family":"Seke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Widmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Clement","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Syndikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kliment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Wedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Boehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Dall\u2019Oglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Franz\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Petrenciuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Staudacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20 Pt 2","key":"10.1016\/j.eururo.2017.06.021_bib0130","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.021_bib0135","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2017.06.021_bib0140","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.021_bib0145","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.021_bib0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2014.02.003","article-title":"Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity","volume":"91","author":"Schutz","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0155","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.021_bib0160","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2017.06.021_bib0165","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.06.021_bib0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.021_bib0175","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.6028\/jres.120.004","article-title":"Revision of the NIST standard for 223Ra: new measurements and review of 2008 data","volume":"120","author":"Zimmerman","year":"2015","journal-title":"J Res Natl Inst Stand Technol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","article-title":"Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial","volume":"15","author":"Vogelzang","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2017.06.021_bib0195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2016.06.002","article-title":"Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial","volume":"70","author":"Parker","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0200","unstructured":"Zytiga\u00ae (abiraterone acetate) tablets for oral administration [prescribing information]. Horsham, PA: Janssen Biotech; 2015. https:\/\/www.zytiga.com."},{"key":"10.1016\/j.eururo.2017.06.021_bib0205","unstructured":"Xtandi\u00ae (enzalutamide) capsules for oral use [prescribing information]. Astellas Pharma: Northbrook, IL; 2015. https:\/\/www.xtandihcp.com\/dosing-and-administration."},{"key":"10.1016\/j.eururo.2017.06.021_bib0210","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.021_bib0215","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.021_bib0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1758834016656493","article-title":"Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors","volume":"8","author":"Verzoni","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0225","unstructured":"Taxotere\u00ae (docetaxel) injection concentrate, intravenous infusion (IV) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2015. http:\/\/products.sanofi.us\/taxotere\/taxotere.html."},{"key":"10.1016\/j.eururo.2017.06.021_bib0230","unstructured":"Jevtana\u00ae (cabazitaxel) injection, for intravenous use [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2015. http:\/\/products.sanofi.us\/jevtana\/jevtana.html."},{"key":"10.1016\/j.eururo.2017.06.021_bib0235","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/fon.14.157","article-title":"Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer","volume":"11","author":"Borso","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2017.06.021_bib0240","first-page":"Cd003347","article-title":"Radioisotopes for metastatic bone pain","volume":"7","author":"Roque","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2017.06.021_bib0245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique","volume":"110","author":"Murray","year":"2014","journal-title":"Radiother Oncol"},{"issue":"Suppl 2S","key":"10.1016\/j.eururo.2017.06.021_bib0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/jco.2016.34.2_suppl.197","article-title":"Radium-223 (Ra-223) re-treatment (Re-tx): first experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC)","volume":"34","author":"Sartor","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381730516X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381730516X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T14:18:23Z","timestamp":1529677103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381730516X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S030228381730516X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.06.021","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}